Last reviewed · How we verify
DRM02
DRM02 is a monoclonal antibody that targets CD40L.
DRM02 is a monoclonal antibody that targets CD40L. Used for Plaque psoriasis.
At a glance
| Generic name | DRM02 |
|---|---|
| Sponsor | Dermira, Inc. |
| Drug class | monoclonal antibody |
| Target | CD40L |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
DRM02 works by binding to CD40L, a protein involved in the activation of immune cells, thereby reducing inflammation and modulating the immune response.
Approved indications
- Plaque psoriasis
Common side effects
- Injection site reactions
- Fatigue
- Headache
Key clinical trials
- A Safety and Efficacy Study of DRM02 in Subjects With Rosacea (PHASE2)
- A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis (PHASE2)
- A Safety and Efficacy Study of DRM02 in Subjects With Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DRM02 CI brief — competitive landscape report
- DRM02 updates RSS · CI watch RSS
- Dermira, Inc. portfolio CI